RVNC
Revance Therapeutics, Inc.
NASDAQ: RVNC · HEALTHCARE · BIOTECHNOLOGY
$3.65
+0.00% today
Updated 2026-04-30
Market cap
$381.02M
P/E ratio
—
P/S ratio
1.48x
EPS (TTM)
$-3.34
Dividend yield
—
52W range
$0 – $0
Volume
4.1M
Revance Therapeutics, Inc. (RVNC) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$3.65
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$10.56
Financial forecast
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.1B | $0.1B | $0.2B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -71.80%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.